Accéder au contenu
Merck

RNF4 sustains Myc-driven tumorigenesis by facilitating DNA replication.

The Journal of clinical investigation (2024-03-26)
Joonyoung Her, Haiyan Zheng, Samuel F Bunting
RÉSUMÉ

The mammalian SUMO-targeted E3 ubiquitin ligase Rnf4 has been reported to act as a regulator of DNA repair, but the importance of RNF4 as a tumor suppressor has not been tested. Using a conditional-knockout mouse model, we deleted Rnf4 in the B cell lineage to test the importance of RNF4 for growth of somatic cells. Although Rnf4-conditional-knockout B cells exhibited substantial genomic instability, Rnf4 deletion caused no increase in tumor susceptibility. In contrast, Rnf4 deletion extended the healthy lifespan of mice expressing an oncogenic c-myc transgene. Rnf4 activity is essential for normal DNA replication, and in its absence, there was a failure in ATR-CHK1 signaling of replication stress. Factors that normally mediate replication fork stability, including members of the Fanconi anemia gene family and the helicases PIF1 and RECQL5, showed reduced accumulation at replication forks in the absence of RNF4. RNF4 deficiency also resulted in an accumulation of hyper-SUMOylated proteins in chromatin, including members of the SMC5/6 complex, which contributes to replication failure by a mechanism dependent on RAD51. These findings indicate that RNF4, which shows increased expression in multiple human tumor types, is a potential target for anticancer therapy, especially in tumors expressing c-myc.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
Cocktails d'inhibiteurs de protéases Mini cOmplete, Tablets provided in a glass vial
Sigma-Aldrich
Anticorps anti-phospho-histone H2A.X (Ser139), clone JBW301, clone JBW301, Upstate®, from mouse
Sigma-Aldrich
Hydroxyurée, 98%, powder
Sigma-Aldrich
Gemcitabine hydrochloride, ≥98% (HPLC)
Sigma-Aldrich
RAD51 Inhibitor B02, ≥98% (HPLC)